Acrivon Therapeutics (NASDAQ:ACRV) PT Raised to $25.00

Acrivon Therapeutics (NASDAQ:ACRV) had its price objective upped by stock analysts at BMO Capital Markets from $18.00 to $25.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 194.81% from the stock’s current price.

ACRV has been the topic of a number of other reports. LADENBURG THALM/SH SH lowered their target price on shares of Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, April 5th. Piper Sandler lifted their target price on shares of Acrivon Therapeutics from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Acrivon Therapeutics in a report on Thursday. Finally, JMP Securities boosted their target price on shares of Acrivon Therapeutics from $14.00 to $17.00 and gave the stock a “market outperform” rating in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $22.63.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $8.48. 188,210 shares of the company’s stock traded hands, compared to its average volume of 603,051. The company has a market cap of $191.99 million, a price-to-earnings ratio of -3.07 and a beta of 1.94. The company’s 50 day simple moving average is $6.56 and its 200 day simple moving average is $5.35. Acrivon Therapeutics has a 52 week low of $3.19 and a 52 week high of $14.30.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Thursday, March 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). As a group, equities research analysts predict that Acrivon Therapeutics will post -3.3 earnings per share for the current year.

Insider Buying and Selling

In other news, major shareholder Perceptive Advisors Llc acquired 2,353,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the completion of the acquisition, the insider now owns 5,360,858 shares in the company, valued at $45,567,293. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.30% of the stock is currently owned by insiders.

Institutional Trading of Acrivon Therapeutics

A hedge fund recently raised its stake in Acrivon Therapeutics stock. Exchange Traded Concepts LLC lifted its holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,289 shares of the company’s stock after purchasing an additional 3,370 shares during the quarter. Exchange Traded Concepts LLC owned 0.06% of Acrivon Therapeutics worth $65,000 as of its most recent SEC filing. 71.62% of the stock is currently owned by hedge funds and other institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.